Irna Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 1.50 M
About Irna Pharmaceuticals
Irna Pharmaceuticals Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 July 2011 and has a history of 13 years and seven months. Its registered office is in Muzaffarpur, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹1.50 M.
Arif Abbas, Anwar Ali, Chandan Gitesh, and One other member serve as directors at the Company.
Company Details
- Location
Muzaffarpur, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51397BR2011PTC017176
- Company No.
017176
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jul 2011
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Irna Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arif Abbas  | Director | 07-Jul-2011 | Current |
| Anwar Ali | Director | 31-Jan-2013 | Current |
| Chandan Gitesh | Director | 31-Jan-2013 | Current |
| Tehzeeb Abidi | Director | 31-Jan-2013 | Current |
Financial Performance of Irna Pharmaceuticals.
Enhance accessibility to Irna Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Irna Pharmaceuticals?
Unlock access to Irna Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Seasain Auto Private LimitedAnwar Ali and Chandan Gitesh are mutual person
Charges (Loans)
₹1.50 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Apr 2012 | Bank Of India | ₹1.25 M | Open |
| 23 Apr 2012 | Bank Of India | ₹0.25 M | Open |
How Many Employees Work at Irna Pharmaceuticals?
Unlock and access historical data on people associated with Irna Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Irna Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Irna Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
